Generative AI and its Impact on Speed to Market for Pharmaceuticals
Did you know that it takes approximately seven years to develop and bring a new drug to market? However, this time can be significantly reduced…
Did you know that it takes approximately seven years to develop and bring a new drug to market? However, this time can be significantly reduced…
Smart analytics applied to real-world data are increasingly enabling companies to track adverse effects, while at the same time identifying opportunities for drug repurposing. ArisGlobal’s…
The breakneck pace of digital transformation spurred by COVID-19 continued to reshape the life sciences landscape in 2023. Rather than a single watershed moment, this…
Arriello’s Kate Coleman discusses how best to tackle the five key priorities for getting the most from your approach to quality and risk in 2024….
The new Third-Party Audit Report Library (3PARL®) consortium, founded by Rephine and Eurofins Healthcare, aims to set a benchmark for life sciences manufacturing supply chain…
In the intensely competitive clinical trial environment, the ability of sponsors to pay research sites consistently and transparently is a growing concern. Traditional methods are…
Highly manual processes, specific local market requirements, and tool usage inconsistencies have impeded global information visibility and flow, adding risk to key regulatory processes. More…
With the end of the year quickly approaching, you will likely see multiple articles on the key trends of 2023 and predictions for 2024 start…
Despite a step change in awareness about the need for diverse participants in clinical trials, ongoing clinical trials in western health systems fail to reflect…
Liquid biopsies — blood tests that provide an alternative to traditional surgical biopsies — are making it easier to detect, monitor, and treat cancer. In fact, liquid…